CrossRef enabled

PAC Archives

Archive →

Pure Appl. Chem., 2009, Vol. 81, No. 6, pp. 1051-1063

Published online 2009-05-05

Discovery of anticancer agents of diverse natural origin

A. Douglas Kinghorn1*, Esperanza J. Carcache de Blanco1, Hee-Byung Chai1, Jimmy Orjala2, Norman R. Farnsworth2, D. Doel Soejarto2, Nicholas H. Oberlies3, Mansukh C. Wani3, David J. Kroll3*, Cedric J. Pearce4, Steven M. Swanson2, Robert A. Kramer5, William C. Rose5, Craig R. Fairchild5, Gregory D. Vite5, Stuart Emanuel5, David Jarjoura6 and Frederick O. Cope6

1 College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
2 College of Pharmacy, The University of Illinois at Chicago, Chicago, IL 60612, USA
3 Research Triangle Institute, Research Triangle Park, NC 27709, USA
4 Mycosynthetix, Inc., Hillsborough, NC 27278, USA
5 Bristol-Myers Squibb, Pharmaceutical Research Institute, Princeton, NJ 08543, USA
6 Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA

Abstract: A collaborative multidisciplinary research project is described in which new natural product anticancer drug leads are obtained from a diverse group of organisms, constituted by tropical plants, aquatic cyanobacteria, and filamentous fungi. Information is provided on how these organisms are collected and processed. The types of bioassays are indicated in which crude extracts of these acquisitions are tested. Progress made in the isolation of lead bioactive secondary metabolites from three tropical plants is discussed.